Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 135 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Myocardial Ischemia Clear all
Completed Not applicable Interventional Results available

EXCEL Clinical Trial

NCT01205776
View directory record Official record
Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Percutaneous Coronary Intervention, CABG
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 11, 2026, 10:17 AM EDT
Completed No phase listed Observational

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

NCT00545610
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Not listed
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 81 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Oct 11, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

NCT02539160
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 11, 2026, 10:17 AM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 11, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

NCT01763996
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Febuxostat, Febuxostat placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 11, 2026, 10:17 AM EDT
Completed No phase listed Observational

CREATION Health Readmission Risk Assessment Tool

NCT03424382
View directory record Official record
Conditions
Heart Failure, COPD, Myocardial Infarction, Coronary Artery Bypass Graft, Pneumonia, Total Knee Replacement, Total Hip Replacement, Stroke
Interventions
Not listed
Lead sponsor
AdventHealth
Other
Eligibility
21 Years and older
Enrollment
1,218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 11, 2026, 10:17 AM EDT
Completed No phase listed Observational

Patient and Provider Assessment of Lipid Management Registry

NCT02341664
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 11, 2026, 10:17 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 10:17 AM EDT
Withdrawn Phase 4 Interventional

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

NCT00657514
View directory record Official record
Conditions
Peripheral Arterial Disease, Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 11, 2026, 10:17 AM EDT
Completed Not applicable Interventional

Sapphire 3 CTO Study

NCT06358508
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
Interventions
Sapphire 3 Coronary Dilatation Catheter
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Stanford, California • Torrance, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 11, 2026, 10:17 AM EDT
Active, not recruiting Not applicable Interventional

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

NCT03674307
View directory record Official record
Conditions
Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
Interventions
No screening, Regular Screening
Other
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
3,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 11, 2026, 10:17 AM EDT
Completed No phase listed Observational

Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

NCT02026466
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Mesa, Arizona • Phoenix, Arizona • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 11, 2026, 10:17 AM EDT
Enrolling by invitation Not applicable Interventional

Acolyte CTO-PCI Study: Imaging and Catheter System to Treat Patients With Coronary Chronic Total Occlusion, Who Have Persistent Symptoms Following Medical Therapy and Are Undergoing Percutaneous Coronary Interventional Procedures

NCT06795763
View directory record Official record
Conditions
Coronary Chronic Total Occlusions, Ischemic Heart Disease, Ischemic Heart Disease (IHD), Ischemic Heart Disease Chronic
Interventions
CTO-PCI Procedure with Acolyte Catheter System
Device
Lead sponsor
Elumn8 Medical
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Roslyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 11, 2026, 10:17 AM EDT
Withdrawn Phase 1 Interventional

REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts

NCT01496209
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Chronic Ischemic Cardiomyopathy
Interventions
Endomyocardial injections of allogeneic Human CSps, Endomyocardial injections of vehicle only.
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 11, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 11, 2026, 10:17 AM EDT
Not listed Phase 2 Interventional

Metformin for HIV Inflammation

NCT02383563
View directory record Official record
Conditions
HIV, Coronary Artery Disease
Interventions
metformin extended release
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 11, 2026, 10:17 AM EDT
Not listed No phase listed Observational

Cardiorenal Risk Stratification Pilot Study

NCT03628443
View directory record Official record
Conditions
Cardio-Renal Syndrome, Heart Failure, Chronic Kidney Diseases
Interventions
Fibroblast Growth Factor 23
Diagnostic Test
Lead sponsor
Coney Island Hospital, Brooklyn, NY
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 11, 2026, 10:17 AM EDT
Terminated Early Phase 1 Interventional Results available

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

NCT00763035
View directory record Official record
Conditions
Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
Interventions
Regadenoson, Dobutamine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 11, 2026, 10:17 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI

NCT02499666
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Percutaneous Coronary Intervention, Coronary stent, Clopidogrel
Procedure · Device · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 11, 2026, 10:17 AM EDT
Completed Not applicable Interventional

Mindfulness & Stress Management Study for Cardiac Patients

NCT02722213
View directory record Official record
Conditions
Heart Diseases, Heart Failure, Myocardial Infarction, Chronic Stable Angina, Coronary Artery Bypass, Angioplasty
Interventions
Mindfulness-Based Stress Reduction (MBSR).
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 11, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

Peripheral Nerve Blocks for Above-the-knee Amputations

NCT03404180
View directory record Official record
Conditions
Peripheral Vascular Diseases, Hyperglycaemia (Diabetic), Hypertension, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions
Peripheral nerve block, Intravenous Sedatives, Lateral femoral cutaneous nerve blocks, Obturator nerve blocks
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 11, 2026, 10:17 AM EDT
Completed Not applicable Interventional

Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function

NCT00554242
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Grape seed extract and ascorbic acid
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2009 · Synced Oct 11, 2026, 10:17 AM EDT
Not listed Phase 4 Interventional

Safety of Amiodarone and Ranolazine Together in Patients With Angina

NCT01558830
View directory record Official record
Conditions
Chronic Stable Angina, Coronary Artery Disease, Atrial Fibrillation, Ventricular Tachycardia
Interventions
ranolazine, placebo
Drug
Lead sponsor
Cardiovascular Consultants of Nevada
Other
Eligibility
35 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Henderson, Nevada • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 11, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin Dose and Atherosclerosis in Patients With Heart Disease

NCT00272337
View directory record Official record
Conditions
Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction
Interventions
Aspirin
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
2
States / cities
Atlantis, Florida • Tamarac, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 11, 2026, 10:17 AM EDT